Ginkgo Bioworks Holdings, Inc. (DNA, Financial) experienced a notable stock movement, with shares increasing by 5.19%. The stock is currently priced at $6.69 per share, with a trading volume of 510,446 shares and a turnover rate of 0.89%. The stock's amplitude reached 6.05%.
According to the latest financial report, Ginkgo Bioworks reported a revenue of $89.05 million, a net loss of $56.40 million, and an earnings per share of -$1.08. The company's gross profit stood at $59.87 million, with a price-to-earnings ratio of -0.52.
Among six rating institutions, 17% recommended buying the stock, another 17% suggested holding, while 66% advised selling. In the broader biotechnology sector, where Ginkgo Bioworks operates, the overall increase was 0.61%.
Other notable stocks in the sector included Neurosense Therapeutics Ltd, Cidara Therapeutics, Inc., and Briacell Therapeutics Corp., which saw significant gains. Active stocks included Biodexa Pharmaceuticals Plc, Conduit Pharmaceuticals Inc., and Tff Pharmaceuticals, Inc., with turnover rates of 962.12%, 532.28%, and 397.68%, respectively. Stocks with high volatility included Conduit Pharmaceuticals Inc., Biodexa Pharmaceuticals Plc, and Silexion Therapeutics Corp, with amplitudes of 162.20%, 84.16%, and 76.33%.
Ginkgo Bioworks is a cell programming platform offering comprehensive services across various markets, including food, agriculture, pharmaceuticals, and specialty chemicals. The company operates through two segments: Foundry and Biosecurity, with the latter generating most of its revenue from data analysis and service fees.
